UPenn vs. Genentech: HER2 Drug Patents Dismissed With Prejudice

Case Overview

The Parties

The Patents at Issue

Two U.S. patents formed the core of UPenn’s infringement allegations:

• • US6417168B1 — A foundational patent covering compositions and methods relating to HER2 antibody technology.
• • US7625558B2 — A continuation-family patent extending protection over related antibody-based therapeutic methods.

Both patents implicate core molecular biology claims around HER2-receptor targeting — claims that sit at the commercial heart of Genentech’s oncology portfolio.

The Accused Products

UPenn alleged infringement across four Genentech products:

• • **Herceptin (trastuzumab)** — First-line HER2+ breast cancer standard of care
• • **Perjeta (pertuzumab)** — Used in combination with trastuzumab for HER2+ breast cancer
• • **Herceptin Hylecta (trastuzumab and hyaluronidase-oysk)** — Subcutaneous formulation of Herceptin
• • **Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf)** — Fixed-dose combination subcutaneous product

Legal Representation

Plaintiff (UPenn): Farnan LLP (Brian E. Farnan, Michael J. Farnan, and nine additional counsel), a Delaware-based firm known for IP litigation before the District Court.

Defendant (Genentech): Morris, Nichols, Arsht & Tunnell LLP, with a team including Daralyn J. Durie and Karen Jacobs, alongside eleven additional defense counsel.

Litigation Timeline & Procedural History

The case was filed in Delaware — the preeminent venue for U.S. patent litigation — where concentrated judicial experience with complex IP matters and predictable procedural timelines make it a preferred forum for plaintiffs asserting sophisticated biotechnology patents.

At 1,138 days, the case duration reflects the complexity typical of multi-patent, multi-product biopharmaceutical litigation, where claim construction disputes, expert discovery on scientific validity, and potential IPR (inter partes review) proceedings at the USPTO commonly extend timelines. The case did not advance to trial, closing instead via stipulated dismissal — suggesting a negotiated resolution reached before the parties committed to the costs and risks of full adjudication.

Chief Judge Jennifer L. Hall, presiding over the District of Delaware, has accumulated significant experience in patent-intensive matters, making her courtroom a rigorous environment for both validity and infringement arguments.

The Verdict & Legal Analysis

Outcome

The case was terminated pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii) — a stipulated dismissal signed by counsel for both parties. All claims and counterclaims were dismissed with prejudice, with each party bearing its own costs, fees, and expenses. No damages amount was publicly disclosed.

What “Dismissed With Prejudice” Signals

A Rule 41(a)(1)(A)(ii) dismissal with prejudice is procedurally significant. Unlike a dismissal without prejudice — which preserves the plaintiff’s right to re-file — a with-prejudice dismissal permanently bars UPenn from reasserting these specific claims against Genentech on the same patents. This is a substantive concession by the plaintiff.

Critically, the “each party bears its own costs” language is standard settlement language, suggesting the parties reached a private resolution without a court ruling on the merits. The specific financial terms — licensing payments, royalties, or other consideration — were not disclosed in the public record.

Verdict Cause Analysis

The operative cause of action was patent infringement. In biopharmaceutical cases of this nature, the core legal battlegrounds typically include:

• • Claim Construction: How the court interprets the scope of patent claims — particularly method claims covering antibody administration — is outcome-determinative. Narrow claim construction can eliminate infringement; broad construction invites validity challenges.
• • Validity Challenges: Defendants in foundational antibody patent cases routinely challenge under 35 U.S.C. §§ 102 (anticipation), 103 (obviousness), and 112 (written description and enablement). For patents with priority dates in the late 1990s and early 2000s — as suggested by the application numbers here — prior art landscapes are well-developed.
• • Infringement Analysis: With four accused products spanning both intravenous and subcutaneous formulations, UPenn’s infringement theory would have needed to map each product to specific patent claims — a technically demanding exercise given the molecular complexity of HER2 biologics.

The private resolution prior to trial means no published claim construction order or liability ruling exists in this case’s record — limiting its direct precedential value but not its strategic significance.

Legal Significance

Because the dismissal preceded any substantive judicial ruling, Case No. 1:22-cv-00145 creates no binding precedent on HER2 antibody patent claim construction or validity. However, the case remains significant as a data point: a major academic patent holder targeted the full commercial HER2 franchise of a top-tier pharmaceutical company and negotiated a with-prejudice exit — a pattern that frequently reflects either a licensing agreement or a litigation risk calculus favoring settlement.

Strategic Takeaways

For Patent Holders (Universities & Research Institutions):

• • Academic institutions can effectively leverage foundational biotechnology patents against commercial manufacturers even without manufacturing capacity.
• • Multi-product infringement allegations across an entire therapeutic franchise maximize settlement leverage.
• • Delaware District Court remains a favorable plaintiff venue for complex biotech assertions.

For Accused Infringers (Biopharmaceutical Companies):

• • Early resolution through private negotiation avoids the risk of adverse claim construction orders that could affect patent portfolios beyond the immediate case.
• • Comprehensive defense teams spanning both Delaware local counsel and specialized IP litigators (as Genentech assembled) are essential for multi-patent, multi-product disputes.

For R&D and Freedom-to-Operate (FTO) Analysis:

• • Companies developing HER2-targeted therapies — including biosimilar developers — should conduct FTO analysis against UPenn’s patent portfolio, particularly patents in the US6417168 and US7625558 families.
• • Subcutaneous reformulations of established biologics (Herceptin Hylecta, Phesgo) do not automatically escape infringement liability under method or composition claims.

Industry & Competitive Implications

The UPenn v. Genentech dispute sits within a broader pattern of academic institutions asserting foundational biotechnology IP against commercial beneficiaries of their research. As HER2-targeted therapies approach and enter the biosimilar era — with multiple trastuzumab biosimilars already FDA-approved — the underlying patent landscape becomes increasingly contested terrain.

For biosimilar developers and follow-on biologic manufacturers, this case underscores that method and composition patents held by academic assignees can impose infringement risk independent of the original drug patents. A biosimilar approved against Herceptin’s reference product listing does not automatically obtain freedom to operate under upstream research patents.

From a licensing perspective, the with-prejudice dismissal structure suggests UPenn may have achieved a licensing arrangement — a model other research universities are actively pursuing as technology transfer offices become more sophisticated in patent monetization strategies.

The case also reflects growing litigation activity at the intersection of academic IP and billion-dollar biopharmaceutical franchises — a trend patent professionals should monitor as mRNA, gene therapy, and next-generation antibody platforms generate new foundational IP at research institutions.

Frequently Asked Questions

What patents were involved in UPenn v. Genentech (1:22-cv-00145)?

Two patents: US6417168B1 and US7625558B2, both relating to HER2 antibody technology, assigned to The Trustees of the University of Pennsylvania.

Why was the case dismissed with prejudice?

The parties jointly stipulated to dismissal under Fed. R. Civ. P. 41(a)(1)(A)(ii), with each bearing its own costs — standard language suggesting a negotiated resolution. No court ruling on the merits was issued.

How does this affect HER2 patent litigation broadly?

It signals that academic patent holders remain active asserters against commercial HER2 therapy portfolios and that biosimilar and next-generation HER2 product developers must account for upstream research institution patents in FTO analyses.

For more HER2 antibody patent litigation analysis, explore the USPTO patent database entries for US6417168B1 and US7625558B2, or access the case docket via PACER (Case No. 1:22-cv-00145, D. Del.).